Cargando…

Bioactive glass BAG-S53P4 for the adjunctive treatment of chronic osteomyelitis of the long bones: an in vitro and prospective clinical study

BACKGROUND: This study aimed to explore the in vitro antibacterial activity of the bioglass BAG S53P4 against multi-resistant microorganisms commonly involved in osteomyelitis and to evaluate its use in surgical adjunctive treatment of osteomyelitis. METHODS: In vitro antibacterial activity of BAG-S...

Descripción completa

Detalles Bibliográficos
Autores principales: Drago, Lorenzo, Romanò, Delia, De Vecchi, Elena, Vassena, Christian, Logoluso, Nicola, Mattina, Roberto, Romanò, Carlo Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3878882/
https://www.ncbi.nlm.nih.gov/pubmed/24325278
http://dx.doi.org/10.1186/1471-2334-13-584
_version_ 1782297882815102976
author Drago, Lorenzo
Romanò, Delia
De Vecchi, Elena
Vassena, Christian
Logoluso, Nicola
Mattina, Roberto
Romanò, Carlo Luca
author_facet Drago, Lorenzo
Romanò, Delia
De Vecchi, Elena
Vassena, Christian
Logoluso, Nicola
Mattina, Roberto
Romanò, Carlo Luca
author_sort Drago, Lorenzo
collection PubMed
description BACKGROUND: This study aimed to explore the in vitro antibacterial activity of the bioglass BAG S53P4 against multi-resistant microorganisms commonly involved in osteomyelitis and to evaluate its use in surgical adjunctive treatment of osteomyelitis. METHODS: In vitro antibacterial activity of BAG-S53P4 against methicillin resistant Staphylococcus aureus and Staphylococcus epidermidis, Pseudomonas aeruginosa and Acinetobacter baumannii isolates was evaluated by means of time kill curves, with colony counts performed after 24, 48 and 72 hours of incubation. In vivo evaluation was performed by prospectively studying a cohort of 27 patients with a clinically and radiologically diagnosed osteomyelitis of the long bones in an observational study. Endpoints were the absence of infection recurrence/persistence at follow-up, no need for further surgery whenever during follow-up and absence of local or systemic side effects connected with the BAG use. RESULTS: In vitro tests regarding the antibacterial activity of BAG S53P4 showed a marked bactericidal activity after 24 hrs against all the tested species. This activity continued in the subsequent 24 hrs and no growth was observed for all strains after 72 hrs. Results of the clinical study evidenced no signs of infection in 24 patients (88.9%) at the follow-up, while 2 subjects showed infection recurrence at 6 months from index operation and one more needed further surgical procedures. BAG-S53P4 was generally well tolerated. CONCLUSIONS: The in vitro and in vivo findings reinforce previous observations on the efficacy of BAG-S53P4 for the treatment of chronic osteomyelitis of the long bones, also in the presence of multi-resistant strains and in immunocompromised hosts, without relevant side effects and without the need for locally adding antibiotics. TRIAL REGISTRATION: Deutschen Register Klinischer Studien (DRKS) unique identifier: DRKS00005332.
format Online
Article
Text
id pubmed-3878882
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-38788822014-01-03 Bioactive glass BAG-S53P4 for the adjunctive treatment of chronic osteomyelitis of the long bones: an in vitro and prospective clinical study Drago, Lorenzo Romanò, Delia De Vecchi, Elena Vassena, Christian Logoluso, Nicola Mattina, Roberto Romanò, Carlo Luca BMC Infect Dis Research Article BACKGROUND: This study aimed to explore the in vitro antibacterial activity of the bioglass BAG S53P4 against multi-resistant microorganisms commonly involved in osteomyelitis and to evaluate its use in surgical adjunctive treatment of osteomyelitis. METHODS: In vitro antibacterial activity of BAG-S53P4 against methicillin resistant Staphylococcus aureus and Staphylococcus epidermidis, Pseudomonas aeruginosa and Acinetobacter baumannii isolates was evaluated by means of time kill curves, with colony counts performed after 24, 48 and 72 hours of incubation. In vivo evaluation was performed by prospectively studying a cohort of 27 patients with a clinically and radiologically diagnosed osteomyelitis of the long bones in an observational study. Endpoints were the absence of infection recurrence/persistence at follow-up, no need for further surgery whenever during follow-up and absence of local or systemic side effects connected with the BAG use. RESULTS: In vitro tests regarding the antibacterial activity of BAG S53P4 showed a marked bactericidal activity after 24 hrs against all the tested species. This activity continued in the subsequent 24 hrs and no growth was observed for all strains after 72 hrs. Results of the clinical study evidenced no signs of infection in 24 patients (88.9%) at the follow-up, while 2 subjects showed infection recurrence at 6 months from index operation and one more needed further surgical procedures. BAG-S53P4 was generally well tolerated. CONCLUSIONS: The in vitro and in vivo findings reinforce previous observations on the efficacy of BAG-S53P4 for the treatment of chronic osteomyelitis of the long bones, also in the presence of multi-resistant strains and in immunocompromised hosts, without relevant side effects and without the need for locally adding antibiotics. TRIAL REGISTRATION: Deutschen Register Klinischer Studien (DRKS) unique identifier: DRKS00005332. BioMed Central 2013-12-10 /pmc/articles/PMC3878882/ /pubmed/24325278 http://dx.doi.org/10.1186/1471-2334-13-584 Text en Copyright © 2013 Drago et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Drago, Lorenzo
Romanò, Delia
De Vecchi, Elena
Vassena, Christian
Logoluso, Nicola
Mattina, Roberto
Romanò, Carlo Luca
Bioactive glass BAG-S53P4 for the adjunctive treatment of chronic osteomyelitis of the long bones: an in vitro and prospective clinical study
title Bioactive glass BAG-S53P4 for the adjunctive treatment of chronic osteomyelitis of the long bones: an in vitro and prospective clinical study
title_full Bioactive glass BAG-S53P4 for the adjunctive treatment of chronic osteomyelitis of the long bones: an in vitro and prospective clinical study
title_fullStr Bioactive glass BAG-S53P4 for the adjunctive treatment of chronic osteomyelitis of the long bones: an in vitro and prospective clinical study
title_full_unstemmed Bioactive glass BAG-S53P4 for the adjunctive treatment of chronic osteomyelitis of the long bones: an in vitro and prospective clinical study
title_short Bioactive glass BAG-S53P4 for the adjunctive treatment of chronic osteomyelitis of the long bones: an in vitro and prospective clinical study
title_sort bioactive glass bag-s53p4 for the adjunctive treatment of chronic osteomyelitis of the long bones: an in vitro and prospective clinical study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3878882/
https://www.ncbi.nlm.nih.gov/pubmed/24325278
http://dx.doi.org/10.1186/1471-2334-13-584
work_keys_str_mv AT dragolorenzo bioactiveglassbags53p4fortheadjunctivetreatmentofchronicosteomyelitisofthelongbonesaninvitroandprospectiveclinicalstudy
AT romanodelia bioactiveglassbags53p4fortheadjunctivetreatmentofchronicosteomyelitisofthelongbonesaninvitroandprospectiveclinicalstudy
AT devecchielena bioactiveglassbags53p4fortheadjunctivetreatmentofchronicosteomyelitisofthelongbonesaninvitroandprospectiveclinicalstudy
AT vassenachristian bioactiveglassbags53p4fortheadjunctivetreatmentofchronicosteomyelitisofthelongbonesaninvitroandprospectiveclinicalstudy
AT logolusonicola bioactiveglassbags53p4fortheadjunctivetreatmentofchronicosteomyelitisofthelongbonesaninvitroandprospectiveclinicalstudy
AT mattinaroberto bioactiveglassbags53p4fortheadjunctivetreatmentofchronicosteomyelitisofthelongbonesaninvitroandprospectiveclinicalstudy
AT romanocarloluca bioactiveglassbags53p4fortheadjunctivetreatmentofchronicosteomyelitisofthelongbonesaninvitroandprospectiveclinicalstudy